1-2 of 2
Maarten R. Seefat
Close
Sort by
Journal Articles

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Febe Smits, Kaz Groen, Mark-David Levin, Claudia Stege, Roel JW Van Kampen, Ellen Van Der Spek, Yavuz M Bilgin, Noortje Thielen, Inger S. Nijhof, Inge Ludwig, Esther G.M. De Waal, Yorick Sandberg, Alain Kentos, Gert Jan Timmers, Josien C Regelink, Matthijs Westerman, Koen de Heer, Marie Christiane Vekemans, Nazik Durdu-Rayman, Nicole de Graauw, Maarten R. Seefat, Niels WCJ van de Donk, Paula F Ypma, Kazem Nasserinejad, Sonja Zweegman
Journal: Blood
Blood (2023) 142 (Supplement 1): 342.
https://doi.org/10.1182/blood-2023-180006
Published: 2023
Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. Van Kampen, Maria B.L. Leijs, Noortje Thielen, Matthijs Westerman, Ka Lung Wu, Inge Ludwig, Djamila Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Pieter Sonneveld, Maarten R. Seefat, Fransien Croon-de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. De Waal, Maaike Sohne, Paula F Ypma, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 80.
https://doi.org/10.1182/blood-2021-152112
Published: 2021